Studies show that reduced m6A modification levels and decreased expressions of METTL3, METTL14 and YTHDF2 in peripheral blood mononuclear cells (PBMCs) from PD patients emphasize m6A dysregulation’s role in PD pathogenesis [47]. This evidence concerns the gene METTL14 and Parkinson disease.